The central role of BCR-ABL kinase in leukemogenesis promotes it as an ideal target for drug screens to treat CML with the attempts to decrease the amount of the BCR-ABL transcripts and/or to inhibit its tyrosine kinase activity. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.